Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents.

Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, Speicher D, Al-Uzri A, Adu-Darko M, Payne EH, Gelber CE, Lin S, Harper B, Melloni C, Cohen-Wolkowiez M, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee.

J Clin Pharmacol. 2019 Jul 17. doi: 10.1002/jcph.1499. [Epub ahead of print]

PMID:
31317556
2.

Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya.

Mbae M, Owen L, Elisha KK, Ndhere A, Mugambi NS, Yogev R, Murphy RL, Jarvis JN.

AIDS. 2019 Jul 1;33(8):1404-1406. doi: 10.1097/QAD.0000000000002216. No abstract available.

PMID:
31157666
3.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS.

Am J Perinatol. 2019 Apr 16. doi: 10.1055/s-0039-1681014. [Epub ahead of print]

4.

Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children.

Hornik CP, Gonzalez D, van den Anker J, Atz AM, Yogev R, Poindexter BB, Ng KC, Delmore P, Harper BL, Melloni C, Lewandowski A, Gelber C, Cohen-Wolkowiez M, Lee JH; Pediatric Trial Network Steering Committee.

J Clin Pharmacol. 2018 Apr 20. doi: 10.1002/jcph.1116. [Epub ahead of print]

PMID:
29677389
5.

Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.

Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 Study Team.

J Infect Dis. 2018 Apr 11;217(9):1338-1346. doi: 10.1093/infdis/jiy066.

6.

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.

McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2000 Study Team.

J Infect Dis. 2018 Apr 11;217(9):1347-1355. doi: 10.1093/infdis/jiy040.

7.

Protecting the Community Through Child Vaccination.

Anderson EJ, Daugherty MA, Pickering LK, Orenstein WA, Yogev R.

Clin Infect Dis. 2018 Jul 18;67(3):464-471. doi: 10.1093/cid/ciy142.

PMID:
29471452
8.

A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.

Dallefeld SH, Atz AM, Yogev R, Sullivan JE, Al-Uzri A, Mendley SR, Laughon M, Hornik CP, Melloni C, Harper B, Lewandowski A, Mitchell J, Wu H, Green TP, Cohen-Wolkowiez M.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):419-430. doi: 10.1007/s10928-018-9576-y. Epub 2018 Feb 12.

9.

Vital signs analysis algorithm detects inflammatory response in premature infants with late onset sepsis and necrotizing enterocolitis.

Mithal LB, Yogev R, Palac HL, Kaminsky D, Gur I, Mestan KK.

Early Hum Dev. 2018 Feb;117:83-89. doi: 10.1016/j.earlhumdev.2018.01.008. Epub 2018 Jan 23.

10.

Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates.

Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, James LP, Melloni C, Harper B, Mitchell J, Benjamin DK Jr, Boakye-Agyeman F, Cohen-Wolkowiez M.

Ther Drug Monit. 2018 Feb;40(1):103-108. doi: 10.1097/FTD.0000000000000466.

11.

Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.

Autmizguine J, Melloni C, Hornik CP, Dallefeld S, Harper B, Yogev R, Sullivan JE, Atz AM, Al-Uzri A, Mendley S, Poindexter B, Mitchell J, Lewandowski A, Delmore P, Cohen-Wolkowiez M, Gonzalez D; the Pediatric Trials Network Steering Committee.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01813-17. doi: 10.1128/AAC.01813-17. Print 2018 Jan.

12.

Multisite Evaluation of the BD Max Extended Enteric Bacterial Panel for Detection of Yersinia enterocolitica, Enterotoxigenic Escherichia coli, Vibrio, and Plesiomonas shigelloides from Stool Specimens.

Simner PJ, Oethinger M, Stellrecht KA, Pillai DR, Yogev R, Leblond H, Mortensen J.

J Clin Microbiol. 2017 Nov;55(11):3258-3266. doi: 10.1128/JCM.00911-17. Epub 2017 Sep 6.

13.

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.

Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF.

Pediatr Infect Dis J. 2017 Aug;36(8):699-704. doi: 10.1097/INF.0000000000001533.

14.

Long-term pulmonary complications in perinatally HIV-infected youth.

Shearer WT, Jacobson DL, Yu W, Siberry GK, Purswani M, Siminski S, Butler L, Leister E, Scott G, Van Dyke RB, Yogev R, Paul ME, Puga A, Colin AA, Kattan M; Pediatric HIV/AIDS Cohort Study.

J Allergy Clin Immunol. 2017 Oct;140(4):1101-1111.e7. doi: 10.1016/j.jaci.2017.01.031. Epub 2017 Mar 6.

15.

Confounding by Indication Limits Conclusions of Study of Palivizumab Effectiveness.

Boyce TG, Yogev R, DeVincenzo JP, Krilov LR.

Pediatrics. 2017 Mar;139(3). pii: e20164247A. doi: 10.1542/peds.2016-4247A. No abstract available.

16.

Less Common Pediatric Infectious Diseases Revisited.

Rosebush J, Yogev R.

Pediatr Ann. 2017 Feb 1;46(2):e40-e41. doi: 10.3928/19382359-20170119-03. No abstract available.

PMID:
28192575
17.

Pharmacokinetics of Clindamycin in Obese and Nonobese Children.

Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny K, Benjamin DK Jr, Smith PB, Cohen-Wolkowiez M, Watt K; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02014-16. doi: 10.1128/AAC.02014-16. Print 2017 Apr.

18.

Lower total and regional grey matter brain volumes in youth with perinatally-acquired HIV infection: Associations with HIV disease severity, substance use, and cognition.

Lewis-de Los Angeles CP, Williams PL, Huo Y, Wang SD, Uban KA, Herting MM, Malee K, Yogev R, Csernansky JG, Nichols S, Van Dyke RB, Sowell ER, Wang L; Pediatric HIV/AIDS Cohort Study (PHACS) and the Pediatric Imaging, Neurocognition, and Genetics (PING) Study.

Brain Behav Immun. 2017 May;62:100-109. doi: 10.1016/j.bbi.2017.01.004. Epub 2017 Jan 10.

19.

Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.

Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, Palazzi DL, Bhatt-Mehta V, Sullivan JE, Zhang L, Murphy J, Ussery XT, Puttagunta S, Dunne MW, Cohen-Wolkowiez M.

Pediatr Infect Dis J. 2017 Jul;36(7):645-653. doi: 10.1097/INF.0000000000001538.

20.

Cord Blood Acute Phase Reactants Predict Early Onset Neonatal Sepsis in Preterm Infants.

Mithal LB, Palac HL, Yogev R, Ernst LM, Mestan KK.

PLoS One. 2017 Jan 3;12(1):e0168677. doi: 10.1371/journal.pone.0168677. eCollection 2017.

21.

Deformed Subcortical Structures Are Related to Past HIV Disease Severity in Youth With Perinatally Acquired HIV Infection.

Lewis-de Los Angeles CP, Alpert KI, Williams PL, Malee K, Huo Y, Csernansky JG, Yogev R, Van Dyke RB, Sowell ER, Wang L; Pediatric HIV/AIDS Cohort Study (PHACS).

J Pediatric Infect Dis Soc. 2016 Dec;5(suppl 1):S6-S14.

22.

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335.

23.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

24.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

25.

Viral Bronchiolitis in Children.

DeVincenzo JP, Krilov LR, Yogev R.

N Engl J Med. 2016 May 5;374(18):1791. doi: 10.1056/NEJMc1601509. No abstract available.

PMID:
27144865
26.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

27.

Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.

Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA 3rd, Tassiopoulos KK, Seage GR 3rd, Seybolt LM, Burchett S, Hazra R; Pediatric HIV/AIDS Cohort Study (PHACS), Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E.

Clin Infect Dis. 2016 Jul 1;63(1):133-137. doi: 10.1093/cid/ciw213. Epub 2016 Apr 7.

28.

Computerized vital signs analysis and late onset infections in extremely low gestational age infants.

Mithal LB, Yogev R, Palac H, Gur I, Mestan KK.

J Perinat Med. 2016 Jul 1;44(5):491-7. doi: 10.1515/jpm-2015-0362.

PMID:
26845716
29.

Antiretroviral Therapy for Nevirapine-Exposed Children With HIV Infection.

Yogev R.

JAMA. 2015 Nov 3;314(17):1801-2. doi: 10.1001/jama.2015.13763. No abstract available.

PMID:
26529157
30.

Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study (PHACS), Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E.

Clin Infect Dis. 2016 Jan 1;62(1):106-114. doi: 10.1093/cid/civ734. Epub 2015 Sep 18.

31.

Default Mode Connectivity in Youth With Perinatally Acquired HIV.

Herting MM, Uban KA, Williams PL, Gautam P, Huo Y, Malee K, Yogev R, Csernansky J, Wang L, Nichols S, Van Dyke R, Sowell ER.

Medicine (Baltimore). 2015 Sep;94(37):e1417. doi: 10.1097/MD.0000000000001417.

32.

Efficacy and effectiveness of live attenuated influenza vaccine in school-age children.

Coelingh K, Olajide IR, MacDonald P, Yogev R.

Expert Rev Vaccines. 2015;14(10):1331-46. doi: 10.1586/14760584.2015.1078732. Epub 2015 Sep 7. Review.

PMID:
26372891
33.

White matter microstructure among youth with perinatally acquired HIV is associated with disease severity.

Uban KA, Herting MM, Williams PL, Ajmera T, Gautam P, Huo Y, Malee KM, Yogev R, Csernansky JG, Wang L, Nichols SL, Sowell ER; Pediatric HIVAIDS Cohort and the Pediatric Imaging, Neurocognition, and Genetics Studies.

AIDS. 2015 Jun 1;29(9):1035-44. doi: 10.1097/QAD.0000000000000648.

34.

Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.

Yogev R, Krilov LR, Fergie JE, Weiner LB.

Pediatr Infect Dis J. 2015 Sep;34(9):958-60. doi: 10.1097/INF.0000000000000808. No abstract available.

PMID:
26107347
35.

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, Knapp KM, Wheeler JJ, Butler L, Hazra R, Miller TL, Seage GR 3rd, Van Dyke RB, Barr E, Davtyan M, Mofenson LM, Rich KC; Pediatric HIV/AIDS Cohort Study.

Clin Infect Dis. 2015 Sep 15;61(6):996-1003. doi: 10.1093/cid/civ437. Epub 2015 Jun 9.

36.

Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots.

Gonzalez D, Melloni C, Poindexter BB, Yogev R, Atz AM, Sullivan JE, Mendley SR, Delmore P, Delinsky A, Zimmerman K, Lewandowski A, Harper B, Lewis KC, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee.

Bioanalysis. 2015;7(9):1137-49. doi: 10.4155/bio.15.38.

37.

Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure.

Himes SK, Tassiopoulos K, Yogev R, Huestis MA; Pediatric HIV/AIDS Cohort Study (PHACS).

J Pediatr. 2015 Aug;167(2):305-11.e3. doi: 10.1016/j.jpeds.2015.04.062. Epub 2015 May 19.

38.

Early viral suppression improves neurocognitive outcomes in HIV-infected children.

Crowell CS, Huo Y, Tassiopoulos K, Malee KM, Yogev R, Hazra R, Rutstein RM, Nichols SL, Smith RA, Williams PL, Oleske J, Muller WJ; PACTG 219C Study Team and the Pediatric HIVAIDS Cohort Study (PHACS).

AIDS. 2015 Jan 28;29(3):295-304. doi: 10.1097/QAD.0000000000000528.

39.

Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012.

Rough K, Tassiopoulos K, Kacanek D, Griner R, Yogev R, Rich KC, Seage GR 3rd; Pediatric HIVAIDS Cohort Study.

AIDS. 2015 Jan 2;29(1):117-23. doi: 10.1097/QAD.0000000000000503.

40.

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.

41.

Clinical characteristics and genotypes of rotavirus in adults.

Anderson EJ, Shippee DB, Tate JE, Larkin B, Bregger MD, Katz BZ, Noskin GA, Sederdahl BK, Shane AL, Parashar UD, Yogev R.

J Infect. 2015 Jun;70(6):683-7. doi: 10.1016/j.jinf.2014.11.012. Epub 2014 Dec 4. No abstract available.

PMID:
25481405
42.

Multicenter clinical evaluation of the novel Alere™ i Influenza A&B isothermal nucleic acid amplification test.

Bell J, Bonner A, Cohen DM, Birkhahn R, Yogev R, Triner W, Cohen J, Palavecino E, Selvarangan R.

J Clin Virol. 2014 Sep;61(1):81-6. doi: 10.1016/j.jcv.2014.06.001. Epub 2014 Jun 7.

43.

Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.

Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee.

Clin Pharmacol Ther. 2014 Oct;96(4):429-37. doi: 10.1038/clpt.2014.134. Epub 2014 Jun 20.

44.

Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.

Crowell CS, Malee KM, Yogev R, Muller WJ.

Rev Med Virol. 2014 Sep;24(5):316-31. doi: 10.1002/rmv.1793. Epub 2014 May 8. Review.

PMID:
24806816
45.

Long-term highly suppressed HIV-infected children and adolescents with negative rapid HIV tests due to significant antibody loss.

Merchant M, Wright M, Kabat W, Yogev R.

J Clin Virol. 2014 Mar;59(3):172-6. doi: 10.1016/j.jcv.2013.11.012. Epub 2013 Dec 5.

PMID:
24440176
46.

Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda.

Ghadrshenas A, Ben Amor Y, Chang J, Dale H, Sherman G, Vojnov L, Young P, Yogev R; Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers and Children.

AIDS. 2013 Nov;27 Suppl 2:S197-205. doi: 10.1097/QAD.0000000000000104. Review.

PMID:
24361629
47.

Addressing and improving the continuum of care for HIV-affected children: challenges and solutions.

Kellerman SE, Sugandhi N, Luo C, McClure C, Yogev R.

AIDS. 2013 Nov;27 Suppl 2:S135-7. doi: 10.1097/QAD.0000000000000129. No abstract available.

PMID:
24361622
48.

Blastomycosis in Children: A Study of 14 Cases.

Anderson EJ, Ahn PB, Yogev R, Jaggi P, Shippee DB, Shulman ST.

J Pediatric Infect Dis Soc. 2013 Dec;2(4):386-90. doi: 10.1093/jpids/pis107. Epub 2013 Jan 9.

PMID:
26619502
49.

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, Dubovsky F.

PLoS One. 2013 Oct 29;8(10):e77104. doi: 10.1371/journal.pone.0077104. eCollection 2013.

50.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

Supplemental Content

Support Center